|
Fetus
|
D005333 |
[The anatomical parts that make up a viviparous mammalian organism in the postembryonic period of development.
, The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN.
, A fetus that is not delivered at the initial PARTURITION of a MULTIPLE PREGNANCY, usually of twins in humans. The retained fetus can progress to term and result in LIVE BIRTH.
] |
|
Fever
|
D005334 |
[An abnormal elevation of body temperature, usually as a result of a pathologic process.
] |
|
Fever of Unknown Origin
|
D005335 |
[Fever in which the etiology cannot be ascertained.
] |
|
Fiber Optic Technology
|
D005336 |
[The technology of transmitting light over long distances through strands of glass or other transparent material.
] |
|
Fibric Acids
|
D058607 |
[Compounds that either share the structure of fibric acid in their molecular arrangement or are considered variants of the fibric acid structure.
] |
|
Fibril-Associated Collagens
|
D024021 |
[A family of non-fibrillar collagens that interact with FIBRILLAR COLLAGENS. They contain short triple helical domains interrupted by short non-helical domains and do not form into collagen fibrils.
] |
|
Fibrillar Collagens
|
D024022 |
[A family of structurally related collagens that form the characteristic collagen fibril bundles seen in CONNECTIVE TISSUE.
] |
|
Fibrillin-1
|
D000071838 |
[A fibrillin (FBN1) that functions as a structural support protein for MICROFIBRILS. It also regulates the maturation of OSTEOBLASTS by controlling the availability and concentration of TGF-BETA and BONE MORPHOGENETIC PROTEINS. Mutations in the FBN1 gene are associated with MARFAN SYNDROME.
] |
|
Fibrillin-2
|
D000071840 |
[A fibrillin (FBN2) that functions to regulate the assembly of ELASTIC FIBERS. Mutations in the FBN2 gene are associated with congenital contractural ARACHNODACTYLY.
] |
|
Fibrillins
|
D000071837 |
[A family of extracellular matrix glycoproteins that is structurally similar to LATENT TGF-BETA BINDING PROTEINS, but contain additional TGF-beta binding domains, in addition to unique domains at their N and C-terminals. Fibrillins assemble into 10-12 nm MICROFIBRILS that function in a variety of cell interactions with the EXTRACELLULAR MATRIX and developmental processes such as ELASTIC TISSUE maintenance and assembly, and the targeting of growth factors to the extracellular matrix.
] |
|
Fibrin
|
D005337 |
[Antithrombin I refers to the capacity of fibrin to absorb or occlude thrombin and thus neutralize (but not inactivate) it.
, A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
] |
|
Fibrin Clot Lysis Time
|
D063285 |
[A measurement of the time needed for FIBRINOLYSIS to occur.
, A measure of the time it takes for dissolution of a FIBRIN clot from the euglobulin fraction of blood.
] |
|
Fibrin Fibrinogen Degradation Products
|
D005338 |
[Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
] |
|
Fibrin Foam
|
D005339 |
[A dry artificial sterile sponge of fibrin prepared by clotting with thrombin a foam or solution of fibrinogen. It is used in conjunction with thrombin as a hemostatic in surgery at sites where bleeding cannot be controlled by more common methods. (From Martindale, The Extra Pharmacopoeia, 30th ed, p648)
] |
|
Fibrin Modulating Agents
|
D050299 |
[Agents that affect the function of FIBRIN in BLOOD COAGULATION. They used as COAGULANTS for HEMORRHAGE or ANTICOAGULANTS for THROMBOSIS.
] |
|
Fibrin Tissue Adhesive
|
D015718 |
[A human plasma-derived fibrin sealant that rapidly forms a clot.
, An autologous or commercial tissue adhesive containing FIBRINOGEN and THROMBIN. The commercial product is a two component system from human plasma that contains more than fibrinogen and thrombin. The first component contains highly concentrated fibrinogen, FACTOR VIII, fibronectin, and traces of other plasma proteins. The second component contains thrombin, calcium chloride, and antifibrinolytic agents such as APROTININ. Mixing of the two components promotes BLOOD CLOTTING and the formation and cross-linking of fibrin. The tissue adhesive is used for tissue sealing, HEMOSTASIS, and WOUND HEALING.
] |
|
Fibrinogen
|
D005340 |
[Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
] |
|
Fibrinogens, Abnormal
|
D015241 |
[Fibrinogens which have a functional defect as the result of one or more amino acid substitutions in the amino acid sequence of normal fibrinogen. Abnormalities of the fibrinogen molecule may impair any of the major steps involved in the conversion of fibrinogen into stabilized fibrin, such as cleavage of the fibrinopeptides by thrombin, polymerization and cross-linking of fibrin. The resulting dysfibrinogenemias can be clinically silent or can be associated with bleeding, thrombosis or defective wound healing.
] |
|
Fibrinolysin
|
D005341 |
[A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
] |
|
Fibrinolysis
|
D005342 |
[The natural enzymatic dissolution of FIBRIN.
] |
